



PRESS RELEASE

Adocia to hold its annual shareholders' meeting on May 28th, 2020 at its headquarter in Lyon

Lyon, April 20th, 2020- 6:00 pm CET - ADOCIA (Euronext Paris: FR0011184241 - ADOC the "Company" and "Adocia"), a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, will hold its annual shareholders' meeting ("AGM") on May 28th, 2020, at 10 am at the Company's headquarter, 115 avenue Lacassagne, 69003, Lyon, France. The notice of this shareholders' meeting serving as convening notice is published today, in the French Bulletin des Annonces Légales Obligatoires ("BALO"), and includes the agenda, the proposed resolutions as well as instructions to participate and vote for this meeting.

This notice is also available on the company's website:

<https://www.adocia.com/investors-welcome/shareholders-meeting/>.

All documentation regarding this AGM will be made available to shareholders in accordance with existing regulations and will be available on the company's website from May 4th, 2020.

Precisions regarding the AGM:

Only shareholders having registered their shares at least two business days prior to the date of the AGM, by midnight Paris time, will be able to participate in the AGM.

Shareholders holding bearer shares ("actions au porteur") will need to obtain a certificate of shareholding ("attestation de participation") from their brokers. This certificate must be attached to the proxy form or to the appropriate voting form if shareholders wish to designate a proxy or vote by post. The "attestation de participation" may replace the admission card for shareholders wishing to attend the AGM in person.

Each shareholder may submit a question in writing to the Board of Directors, this question being treated during the shareholders meeting. Questions should be sent by registered mail with return receipt to the following address: ADOCIA, 115 avenue Lacassagne - 69003 Lyon or electronic communication to the following address: ag2020@adocia.com.

The written question must imperatively be accompanied by a certificate of attendance in order to be treated and must be sent no later than the fourth business day preceding the date of the general meeting. Shareholders may obtain the legal documentation in preparation of the AGM as described in the article R.225-83 of the French Commercial Code by sending a request:

- By regular mail to: Adocia - Service Relations Investisseurs – 115 avenue Lacassagne, 69003 Lyon, or
- By e-mail to: ag2020@adocia.com.

About Adocia

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. In the diabetes field, Adocia's portfolio of injectable treatments is among the largest and most differentiated of the industry, featuring five clinical-stage products. Adocia aims to expand its portfolio towards the treatment of other metabolic diseases and their comorbidities.

The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application. Adocia's clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analog lispro (BioChaperone® Lispro U100 and U200), a combination of basal insulin glargine and rapid-acting insulin lispro (BioChaperone® Combo) and a combination of a prandial insulin with amylin analog pramlintide (M1 PRAM - ADO09). It also includes an aqueous formulation of human glucagon (BioChaperone® Glucagon) for the treatment of hypoglycemia. Adocia preclinical pipeline includes a combination of insulin glargine with GLP-1 receptor agonists (BioChaperone® Glargine GLP-1) for the treatment of diabetes and a ready-to-use combination of glucagon and a GLP-1 receptor agonist (BioChaperone® Glucagon GLP1) for the treatment of obesity. Adocia is also exploring in preclinic the potential of its M1 PRAM combination to treat people with type 2 diabetes suffering from neurological comorbidities, including Alzheimer's disease.

In 2018, Adocia and Chinese insulin leader Tonghua Dongbao entered a strategic alliance. In April 2018, Adocia granted Tonghua Dongbao licenses to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. The licensing agreements included USD 50 million upfront and up to USD 85 million development milestones, plus double-digit royalties on sales. In June 2018, Tonghua Dongbao agreed to manufacture and supply active pharmaceutical ingredients insulin lispro and insulin glargine to Adocia globally, excluding China, to support Adocia's portfolio development and commercialization.

Adocia aims to deliver "Innovative medicine for everyone, everywhere."

To learn more about Adocia, please visit us at www.adocia.com



For more information please contact:

Adocia Gérard Soula Chairman and CEO contactinvestisseurs@adocia.com Ph.: +33 4 72 610 610	Adocia Press Relations Europe MC Services AG Raimund Gabriel adocia@mc-services.eu Ph.: +49 89 210 228 0	Adocia Investor Relations USA The Ruth Group Tram Bui tbui@theruthgroup.com Ph.: +1 646 536 7035
--------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------

Disclaimer

This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the "Risk Factors" section of the Reference Document filed with the French Autorité des marchés financiers on

April 12, 2019 (a copy of which is available at www.adocia.com) and to the development of economic conditions, financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Adocia to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia shares in any jurisdiction.